UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Nathaly Francois, M.d, M.D | Urology | Columbia, MD | $585.18 | $0 |
| Mr. Jack Mohadeb, Pa, PA | Physician Assistant | Brooklyn, NY | $552.04 | $0 |
| Mrs. Devora Singer, Crnp, CRNP | Home Health | Cumberland, MD | $550.79 | $0 |
| Dr. Brandon Sass | Obstetrics & Gynecology | Sugar Land, TX | $547.98 | $0 |
| Andrew Chung, M.d, M.D | Urology | Manassas, VA | $547.70 | $0 |
| Dr. Vladimir Krichevsky, M.d, M.D | Urology | Brooklyn, NY | $541.60 | $0 |
| Robyn Halbrook, Np, NP | Family | Sugar Land, TX | $539.92 | $0 |
| Danielle Manes, Pa-C, PA-C | Physician Assistant | Austin, TX | $538.15 | $0 |
| Doreen Chung, Md, MD | Urology | New Hyde Park, NY | $538.12 | $0 |
| Kelly Anderson, Np, NP | Adult Health | Fort Wayne, IN | $529.16 | $0 |
| Dr. Kelly Johnson, M.d, M.D | Urology | Owings Mills, MD | $521.83 | $0 |
| Kaiser Robertson, M.d, M.D | Urology | Glen Burnie, MD | $510.65 | $0 |
| Jacqueline Zillioux, Md, MD | Urology | Charlottesville, VA | $506.20 | $0 |
| Nicholas Leone, Md, MD | Urology | Baltimore, MD | $491.33 | $0 |
| Mikhail Regelman, Md, MD | Urology | Woodbury, MN | $484.34 | $0 |
| Elliot Paul, Md, MD | Urology | New Hyde Park, NY | $482.03 | $0 |
| Jean Ung, Md, MD | Urology | Winfield, IL | $480.48 | $0 |
| Eric Choe, Md, MD | Urology | Fairfax, VA | $479.68 | $0 |
| Dr. Thomas Rechtschaffen, M.d, M.D | Urology | Yonkers, NY | $475.35 | $0 |
| William Dowling, Md, MD | Specialist | Baltimore, MD | $472.49 | $0 |
| Dr. Anthony Doerr, Md, MD | Urology | Pensacola, FL | $468.31 | $0 |
| Dr. Lauren Gleich, D.o, D.O | Urology | Philadelphia, PA | $466.74 | $0 |
| Nicole Adams, Fnp-C, FNP-C | Acute Care | Pensacola, FL | $464.77 | $0 |
| Dr. Robert Hatfield, M.d, M.D | Urology | Brentwood, TN | $463.75 | $0 |
| Dr. Charles Payne, Md, MD | Urology | Kingsport, TN | $460.87 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.